Itamar Medical Ltd.

37 articles with Itamar Medical Ltd.

• Itamar Medical Announces Appointment of Shane Brown as President – U.S.

  10/19/2020

  Itamar Medical Ltd., a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, announced that Shane Brown has been appointed President – U.S., effective immediately.

• Itamar™ Medical Announces Third Quarter Preliminary Revenue Results and Reinstates Revenue Guidance for Full Year 2020

  10/13/2020

  Itamar Medical Ltd., a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, reported preliminary unaudited revenue results for the third quarter 2020 and announced revenue guidance for the full year 2020.

• Itamar Medical’s WatchPAT™300 Home Sleep Apnea Testing Device Receives Approval in Japan

  10/1/2020

  Itamar Medical Ltd. announced that its flagship WatchPAT™300 Home Sleep Apnea Testing device has been granted PMDA approval for use in the Japanese market, effective September 14, 2020.

• The German Sleep Society (DGSM) Recognizes PAT™ based Technology in its New Sleep-Related Breathing Disorders Guidelines, Further Benefitting Itamar Medical’s Approach to Sleep Apnea Diagnosis

  9/21/2020

  Updated guidelines represent a significant milestone in the adoption of Itamar’s Peripheral Arterial Tonometry (PAT) based Home Sleep Apnea Testing (HSAT) in Europe, following adoption in the UK, Holland, and Sweden

• Itamar Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020

  9/3/2020

  Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced that management will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Conference. Itamar’s management is scheduled to present on Wednesday, September 16, 2020 a

• Prior Authorization Requirement for Itamar’s WatchPAT™ Home Sleep Apnea Test Removed for all Independence Blue Cross Members

  8/31/2020

  Itamar Medical Ltd. announced that effective July 2020, Independence Blue Cross has removed their prior authorization requirement for home sleep apnea tests following an extensive dialog that included presentation of evidence.

• Itamar Medical Announces Participation in Virtual SLEEP 2020 ConferenceAs a platinum sponsor, Itamar Medical’s virtual booth and on-demand content to be offered to SLEEP 2020 attendees

  8/25/2020

  Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced it will be participating in SLEEP 2020, the annual meeting of the American Academy of Sleep Medicine, which is taking place virtually on August 27-30, 2020. “We are looking forward to

• Itamar Medical Reports Second Quarter 2020 Financial Results

  8/11/2020

  Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the second quarter of 2020.

• Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 11, 2020

  7/27/2020

  Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, announced today that it will report its unaudited financial results for the second quarter 2020 before the U.S. market opens on Tuesday, August 11, 2020.

• Itamar Medical Reports First Quarter 2020 Financial Results

  5/27/2020

  - First Quarter 2020 Revenues Increase 38% to $8.4 Million - - WatchPAT™ Revenues Increase 41% to $8.2 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today report

• Itamar Medical Announces Date Change for First Quarter Financial Results and Conference Call to May 27, 2020

  5/19/2020

  Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced it will be moving up the date of its corporate update and release of its unaudited financial results for the first quarter 2020 to Wednesday, May 27, 2020

• Itamar Medical to Report First Quarter Financial Results and Host Conference Call on Thursday, May 28, 2020

  5/14/2020

  Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, announced today that it will report its unaudited financial results for the first quarter 2020 before the U.S. market opens on Thursday, May 28, 2020.

• Itamar Medical Receives CE Mark Approval for its WatchPAT™ ONE, the First Fully Disposable Home Sleep Apnea Test

  5/4/2020

  Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies

• Itamar™ Medical Funds Clinical Study to Evaluate Potential Impact of CPAP Therapy to Patients with COVID-19 

  4/22/2020

  Study conducted at Mount Sinai Hospital in New York City designed to demonstrate benefit of continuous positive airway pressure (CPAP) in delaying or eliminating hospitalization and/or ventilation in patients with COVID-19

• Itamar™ Medical Announces First Quarter 2020 Preliminary Revenue Increase of Approximately 40%

  4/13/2020

  Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today provided an update on actions the Company is taking in response to the COVID-19 pandemic.

• Itamar™ Medical and BetterNight to Join Forces Offering Referred Patients Home Based Virtual-Care Sleep Solution for the Diagnosis and Treatment of Sleep Apnea

  4/6/2020

  Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), today announced that it has entered into an agreement with Sleep Data Diagnostics and its virtual-care platform BetterNight and Sleep Data Holdings, a leading provider of home-based positive airway pressure (PAP) services.

• Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic

  3/20/2020

  Itamar Medical Ltd. (Nasdaq:  ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today released the following letter from its President and CEO, Gilad Glick.

• Itamar™ Medical Reports Record Fourth Quarter and Full Year 2019 Revenues

  3/3/2020

  Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the three-month period and year ended December 31, 2019.

• Itamar™ Medical and Clalit Research Institute Establish Research Collaboration to Explore WatchPAT Signals’ Ability to Predict Health Outcomes Using Existing Big Data and Artificial Intelligence

  3/2/2020

  Itamar Medical Ltd. (Nasdaq:  ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into a research collaboration agreement with Clalit Research Institute (CRI), a subsidiary of Clalit Health Services (CHS), Israel’s largest state-mandated health service organization.

• Itamar™ Medical to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 3, 2020

  2/19/2020

  Itamar Medical Ltd. announced that it will report its unaudited financial results for the fourth quarter and full year 2019 before the U.S. market opens on Tuesday, March 3, 2020.